Indication
Pulmonary blastomycosis
Pulmonary blastomycosis is an invasive fungal respiratory infection caused by inhaling the conidia of thermally dimorphic fungi of the genus *Blastomyces*, primarily *Blastomyces dermatitidis* or *Blastomyces gilchristii*. Read more about Pulmonary blastomycosis
1 drugs 1 manufacturers
Drugs that treat it
Common Pulmonary blastomycosis therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPulmonary blastomycosis is an invasive fungal respiratory infection caused by inhaling the conidia of thermally dimorphic fungi of the genus *Blastomyces*, primarily *Blastomyces dermatitidis* or *Blastomyces gilchristii*.
After deposition in the lower respiratory tract, the organism transitions into a pathogenic yeast phase that elicits a characteristic pyogranulomatous inflammatory response in both immunocompetent and immunocompromised hosts.
Clinical manifestations range from subclinical disease or acute, self-limited pneumonia presenting with fever, cough, and chest pain to chronic, progressive pulmonary illness marked by consolidation, cavitation, or mass-like infiltrates that can mimic tuberculosis or malignancy.
Severe disease can rapidly lead to respiratory failure or acute respiratory distress syndrome, with the potential for hematogenous dissemination to extrapulmonary sites such as the skin, bone, and central nervous system.
- nih.gov
Pulmonary blastomycosis is an invasive fungal respiratory infection caused by inhaling the conidia of thermally dimorphic fungi of the genus *Blastomyces*, primarily *Blastomyces dermatitidis* or *Blastomyces gilchristii* After deposition in the lower respiratory tract, the organism transitions into a pathogenic yeast phase that elicits a characteristic pyogranulomatous inflammatory response in both immunocompetent and immunocompromised hosts
- nih.gov
Pulmonary blastomycosis is an invasive fungal respiratory infection caused by inhaling the conidia of thermally dimorphic fungi of the genus *Blastomyces*, primarily *Blastomyces dermatitidis* or *Blastomyces gilchristii* After deposition in the lower respiratory tract, the organism transitions into a pathogenic yeast phase that elicits a characteristic pyogranulomatous inflammatory response in both immunocompetent and immunocompromised hosts Clinical manifestations range from subclinical diseas...
- nih.gov
Clinical manifestations range from subclinical disease or acute, self-limited pneumonia presenting with fever, cough, and chest pain to chronic, progressive pulmonary illness marked by consolidation, cavitation, or mass-like infiltrates that can mimic tuberculosis or malignancy
- nih.gov
Clinical manifestations range from subclinical disease or acute, self-limited pneumonia presenting with fever, cough, and chest pain to chronic, progressive pulmonary illness marked by consolidation, cavitation, or mass-like infiltrates that can mimic tuberculosis or malignancy
- cdc.gov
Severe disease can rapidly lead to respiratory failure or acute respiratory distress syndrome, with the potential for hematogenous dissemination to extrapulmonary sites such as the skin, bone, and central nervous system
Personalize your experience
Follow Pulmonary blastomycosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.